MedTrace Logo

Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach

NCT04567446 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2024-06-12

No results posted yet for this study

Summary

Multicentric prospective study with collection of biological samples as part of type II research

Conditions

Interventions

OTHER

Stool

collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment

OTHER

Blood sample

20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04567446 on ClinicalTrials.gov